Table 3.
Descriptive analysis of underutilisation and overutilisation of HDL-C testing in the stable target population in 2014
| Demographics | Underutilisation | Overutilisation | ||
| % | (95% CI) | % | (95% CI) | |
| Gender | ||||
| Female | 48.78 | 48.5 to 49.06 | 46.82 | 46.33 to 47.31 |
| Male | 51.22 | 50.94 to 51.5 | 53.18 | 52.69 to 53.67 |
| Age group | ||||
| 18–34 | 0.35 | 0.32 to 0.38 | 0.41 | 0.35 to 0.48 |
| 35–44 | 1.86 | 1.79 to 1.94 | 2.24 | 2.1 to 2.39 |
| 45–54 | 8.15 | 8 to 8.31 | 8.05 | 7.79 to 8.32 |
| 55–64 | 20.83 | 20.6 to 21.06 | 20.1 | 19.71 to 20.50 |
| 65–74 | 31.08 | 30.82 to 31.34 | 32.45 | 31.99 to 32.91 |
| ≥75 | 37.73 | 37.46 to 38 | 36.75 | 36.28 to 37.22 |
| States | ||||
| NSW+ACT | 35.54 | 35.27 to 35.81 | 37.32 | 36.85 to 37.80 |
| VIC+TA | 26.82 | 26.57 to 27.07 | 28.57 | 28.13 to 29.02 |
| SA+NT | 9.39 | 9.23 to 9.56 | 6.96 | 6.71 to 7.21 |
| QLD | 18.43 | 18.21 to 18.65 | 19.53 | 19.14 to 19.92 |
| WA | 9.82 | 9.65 to 9.99 | 7.62 | 7.36 to 7.88 |
ACT, Australia Capital Territory; HDL-C, high-density lipoprotein cholesterol; NSW, New South Wales; NT, Northern Territory; QLD, Queensland; SA, South Australia; TA, Tasmania; VIC, Victoria; WA, Western Australia.